Iguratimod
- Generic Name
- Iguratimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14N2O6S
- CAS Number
- 123663-49-0
- Unique Ingredient Identifier
- 4IHY34Y2NV
- Background
Iguratimod is under investigation in Rheumatoid Arthritis.
- Indication
用于活动性类风湿关节炎。
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Xuzhou Medical University
- Target Recruit Count
- 20
- Registration Number
- NCT06244628
- Locations
- 🇨🇳
Kailin Xu, Xuzhou, Jiangsu, China
Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Yanfeng Hou
- Target Recruit Count
- 117
- Registration Number
- NCT06146972
- Locations
- 🇨🇳
Yanfeng Hou, Jinan, Shandong, China
The Clinical Efficacy of Immunomodulators in RA Patients
- Conditions
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 400
- Registration Number
- NCT05626348
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05302024
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05281068
- Locations
- 🇨🇳
Zhuo-Yu An, Beijing, China
🇨🇳Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China
Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO)
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05216757
The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA
- Conditions
- Interventions
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 100
- Registration Number
- NCT04928066
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT04830644
- Locations
- 🇨🇳
Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Tianjin First Central Hospital, Tianjin, Tianjin, China
Iguratimod in Systemic Sclerosis
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04515706
The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 400
- Registration Number
- NCT03855007
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.